Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL - a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMTC, the I-BFM and the Westhafen-Intercontinental-Group

Blood (2016) 128 (22): 985.

https://doi.org/10.1182/blood.V128.22.985.985

Published: 2016

Journal Articles

Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial

Blood (2014) 124 (21): 209.

https://doi.org/10.1182/blood.V124.21.209.209

Published: 2014

Journal Articles

The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy)

Amer M. Zeidan, MD, Patrick Forde, MD, Heather J. Symons, MD, MHS, Allen R. Chen, MD, PhD, MHS, B. Douglas Smith, MD, Ephraim J. Fuchs, Leo Luznik, Richard J. Jones, Javier Bolaños-Meade, MD

Blood (2013) 122 (21): 4629.

https://doi.org/10.1182/blood.V122.21.4629.4629

Published: 2013

Journal Articles

Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation

Nirali N Shah, MD, Michael J. Borowitz, MD, PhD, Nancy Robey, PA, Christopher Gamper, MD, PhD, Heather J. Symons, MD, MHS, David Loeb, MD, PhD, Alan S Wayne, MD, Allen R. Chen, MD, PhD, MHS

Blood (2012) 120 (21): 4205.

https://doi.org/10.1182/blood.V120.21.4205.4205

Published: 2012

Journal Articles

Factors Predictive of Relapse of Hematologic Malignancies in Pediatric Patients Post Allogeneic Hematopoietic Cell Transplantation

Nirali N Shah, MD, Michael J. Borowitz, MD, PhD, Seth M. Steinberg, PhD, Mary Lefell, PhD, Nancy Robey, PA, Christopher Gamper, MD, PhD, Heather J. Symons, MD, MHS, David Loeb, MD, PhD, Alan S Wayne, MD, Allen R. Chen, MD, PhD, MHS

Blood (2012) 120 (21): 4206.

https://doi.org/10.1182/blood.V120.21.4206.4206

Published: 2012

Journal Articles

Myeloablative Haploidentical Bone Marrow Transplantation with T Cell Replete Grafts and Post-Transplant Cyclophosphamide: Results of a Phase II Clinical Trial,

Heather J. Symons, Allen R. Chen, MD, PhD, MHS, Leo Luznik, Yvette L. Kasamon, Javier Bolanos Meade, MD, Richard J. Jones, Ephraim J. Fuchs

Blood (2011) 118 (21): 4151.

https://doi.org/10.1182/blood.V118.21.4151.4151

Published: 2011

Journal Articles

AHOD0031: A Phase III Study of Dose-Intensive Therapy for Intermediate Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group

Debra l Friedman, MD, MS, Suzanne Wolden, Louis Constine, MD, Lu Chen, PhD, Kathleen M McCarten, MD, T. J Fitzgerald, Pedro De Alarcon, MD, Allen R. Chen, MD, PhD, MHS, Robert Hutchison, MD, Peter Ehrlich, Nathan L. Kobrinsky, MD, FRCP, Meghan Higman, Shirley Hogan, Lorna Roll, Tanya Trippett, Cindy Schwartz, MD

Blood (2010) 116 (21): 766.

https://doi.org/10.1182/blood.V116.21.766.766

Published: 2010

Journal Articles

Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).

Blood (2010) 116 (21): 3481.

https://doi.org/10.1182/blood.V116.21.3481.3481

Published: 2010

Journal Articles

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Heather Symons, MD, MHS, Allen R. Chen, MD, PhD, MHS, M. Sue Leffell, PhD, Marianna Zahurak, M.S., Kathy Schultz, Heather Karaszkiewicz, Leo Luznik, MD, Javier Bolanos Meade, MD, Yvette L. Kasamon, MD, Lode J. Swinnen, MD, Douglas Edward Gladstone, MD, Richard J. Jones, MD, Ephraim Fuchs, MD, MBA

Blood (2010) 116 (21): 2362.

https://doi.org/10.1182/blood.V116.21.2362.2362

Published: 2010

Journal Articles

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors

Blood (2010) 116 (19): 4007–4015.

https://doi.org/10.1182/blood-2010-01-261958

Published: 2010

Includes: Supplemental data

Journal Articles

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

Leo Luznik, Javier Bolaños-Meade, Marianna Zahurak, Allen R. Chen, B. Douglas Smith, Robert Brodsky, Carol Ann Huff, Ivan Borrello, William Matsui, Jonathan D. Powell, Yvette Kasamon, Steven N. Goodman, Allan Hess, Hyam I. Levitsky, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs

Blood (2010) 115 (16): 3224–3230.

https://doi.org/10.1182/blood-2009-11-251595

Published: 2010

Journal Articles

High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up

Robert A. Brodsky, Allen R. Chen, Donna Dorr, Ephraim J. Fuchs, Carol Ann Huff, Leo Luznik, B. Douglas Smith, William H. Matsui, Steven N. Goodman, Richard F. Ambinder, Richard J. Jones

Blood (2010) 115 (11): 2136–2141.

https://doi.org/10.1182/blood-2009-06-225375

Published: 2010

Journal Articles

RBC transfusion and BMT rejection

Allen R. Chen

Blood (2009) 114 (11): 2209–2210.

https://doi.org/10.1182/blood-2009-07-229948

Published: 2009

Journal Articles

Clinical Outcomes of Patients with Recurrent/Refractory Hodgkin Disease Receiving Cyclosporine, Interferon-γ, and Interleukin-2 Immunotherapy To Induce Autoreactivity after Autologous Stem Cell Transplantation with BEAM: A COG Study.

Allen R. Chen, MD, PhD, MHS, Robert Hutchison, MD, Allan Hess, PhD, Sharon Gardner, MD, Tanya Trippett, MD, Pedro de Alarcon, MD, Shirley Hogan, PharmD, Joy Mitchell, CRA, Vickie Massey, MD, Louis S. Constine, MD, Lu Chen, PhD, Cindy L. Schwartz, MD

Blood (2007) 110 (11): 1896.

https://doi.org/10.1182/blood.V110.11.1896.1896

Published: 2007

Journal Articles

Determination of the Maximum Tolerated Dose of Cyclophosphamide in Conjunction with High-Dose Etoposide and Carboplatin Followed by Autologous CD34+ Hematopoietic Rescue in Pediatric Patients with Recurrent/Refractory Solid Tumors.

Michelle P. Hudspeth, MD, Barbara Duffy, M.D., M.P.H., Stephen Noga, M.D., Ph.D., Steven Goodman, M.D., Ph.D, Curt I. Civin, M.D., Ph.D., Allen R. Chen, M.D., Ph.D., M.H.S.

Blood (2006) 108 (11): 5462.

https://doi.org/10.1182/blood.V108.11.5462.5462

Published: 2006

Journal Articles

Treatment of Hepatitis-Associated Aplastic Anemia with High Dose Cyclophosphamide.

William J. Savage, MD, Patricia A. DeRusso, MD, Linda M. Resar, MD, Allen R. Chen, MD, PhD, Meghan A. Higman, MD, PhD, David M. Loeb, MD, PhD, Richard J. Jones, MD, Robert A. Brodsky, MD

Blood (2006) 108 (11): 975.

https://doi.org/10.1182/blood.V108.11.975.975

Published: 2006

Journal Articles

The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy

Lesley A. Simpson, Emily A. Burwell, Kida A. Thompson, Samira Shahnaz, Allen R. Chen, David M. Loeb

Blood (2006) 107 (12): 4695–4702.

https://doi.org/10.1182/blood-2005-10-4025

Published: 2006

Journal Articles

Post-Transplantation Cyclophosphamide (Cy) Reduces Graft Rejection and Graft-Versus-Host Disease (GVHD) after Non-Myeloablative, Partially HLA-Mismatched (Haploidentical) Bone Marrow Transplantation (BMT).

Ephraim J. Fuchs, MD, Leo Lunzik, MD, Allen R. Chen, MD, PhD, Michele Phelps, BSN, Angelita Crawford, Robert A. Brodsky, MD, Richard J. Jones, MD

Blood (2004) 104 (11): 437.

https://doi.org/10.1182/blood.V104.11.437.437

Published: 2004

Journal Articles

Pentostatin: Efficacy in Refractory Chronic GVHD in Children.

David A. Jacobsohn, MD, ScM, Brittan Browning, MS, RD, Kimberly Thormann, RN, CRNP, Meghan Higman, MD, PhD, Michele L. Phelps, RN, Allen R. Chen, MD, PhD, Georgia B. Vogelsang, MD

Blood (2004) 104 (11): 2249.

https://doi.org/10.1182/blood.V104.11.2249.2249

Published: 2004

Journal Articles

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome

Blood (2002) 100 (13): 4337–4343.

https://doi.org/10.1182/blood-2002-04-1216

Published: 2002

NARROW

Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL - a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMTC, the I-BFM and the Westhafen-Intercontinental-Group

Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial

The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy)

Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation

Factors Predictive of Relapse of Hematologic Malignancies in Pediatric Patients Post Allogeneic Hematopoietic Cell Transplantation

Myeloablative Haploidentical Bone Marrow Transplantation with T Cell Replete Grafts and Post-Transplant Cyclophosphamide: Results of a Phase II Clinical Trial,

AHOD0031: A Phase III Study of Dose-Intensive Therapy for Intermediate Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group

Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up

RBC transfusion and BMT rejection

Clinical Outcomes of Patients with Recurrent/Refractory Hodgkin Disease Receiving Cyclosporine, Interferon-γ, and Interleukin-2 Immunotherapy To Induce Autoreactivity after Autologous Stem Cell Transplantation with BEAM: A COG Study.

Determination of the Maximum Tolerated Dose of Cyclophosphamide in Conjunction with High-Dose Etoposide and Carboplatin Followed by Autologous CD34+ Hematopoietic Rescue in Pediatric Patients with Recurrent/Refractory Solid Tumors.

Treatment of Hepatitis-Associated Aplastic Anemia with High Dose Cyclophosphamide.

The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy

Post-Transplantation Cyclophosphamide (Cy) Reduces Graft Rejection and Graft-Versus-Host Disease (GVHD) after Non-Myeloablative, Partially HLA-Mismatched (Haploidentical) Bone Marrow Transplantation (BMT).

Pentostatin: Efficacy in Refractory Chronic GVHD in Children.

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only